Observational Study
Copyright ©The Author(s) 2017.
World J Transplant. Aug 24, 2017; 7(4): 222-234
Published online Aug 24, 2017. doi: 10.5500/wjt.v7.i4.222
Table 3 Immune infiltrate characteristics and outcomes of the kidney transplant patients
Pati-entGrouptivCD4 (%)CD8 (%)CD19 (%)Granzyme B (cells/mm2)IL-17 (cells/mm2)Foxp3 (cells/mm2)CTL/Treg ratioTh17/Treg ratioGFR at BxGFR last follow-upProtei-nuria at BxProtei-nuria last follow-upTime to any rejection (d)Time to doubling of creatinine (d)Time to Tx loss (d)Total follow-up (d)
1ATCMR1313525156853520.118.54.74.28UNKNA38116116
2ATCMR32060601034621492.3033.667.20.510.1628NANA1643
3ATCMR2213035303115730.40.248.130.90UNK92NANA1623
4ATCMR22030253055175610.315.29.50.411.71NANA513513
5ATCMR321858025544193111.80.111.2151.081.61NANA645645
6ATCMR210301510265238.817.930.16.70.39UNK103794111761176
7ATCMR01110201042466.60.649.870.30.320.09NANANA1327
8ATCMR021510013081.5016.96.22.436.66164164164164
9ATCMR2201051044314.447.417.414.32.34UNKNANA759759
10ATCMR1203550158120174.71.225.88.61.532.46404911933933
11ATCMR111105592224.711.5112.144.72.070.07NA520NA950
12ATCMR12020151018544.81.316.415.10.58UNKNANANA917
13ATCMR32080702032232359.30.99.29.21.391.39NANANA1
14ATCMR2202010103862103.96.315.28.26.09UNKNANANA913
15NR01020151036553411.621.18.86.77UNKNA598862862
16NR010510101520.52.543.435.80.131.2NANANA1507
17NR0105151051541.33.841.263.50.390.57NANANA1306
18NR1103530309216322.80.5569.82.42.24NA97411181118
19NR01005021282.70.264.653.23.627.571168NANA1173
20NR1002015102573151.7528.47.13.5UNKNA188520520
21NR1102515108181108.18.120.912.410.597.46NA141163163